Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue

American Journal of Physiology - Endocrinology and Metabolism

Volumn 296, Issue 4, 2009, Pages

  Wu, Haiya ^a   Wei, Li ^a   Bao, Yuqian ^a   Lu, Junxi ^a   Huang, Ping ^b   Liu, Yong ^b   Jia, Weiping ^a   Xiang, Kunsan ^a  

^a Shanghai Clinical Center of Diabetes   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Insulin resistance; Liver

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; RETINOL BINDING PROTEIN 4; SOLVAY; UNCLASSIFIED DRUG; ADIPONECTIN, HUMAN; ANTILIPEMIC AGENT; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN;

ADIPOCYTE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; EPIDIDYMIS FAT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIVER; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ADIPOSE TISSUE; ADULT; ANIMAL; BLOOD; CELL STRAIN 3T3; CLINICAL TRIAL; DOWN REGULATION; GENETICS; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

3T3-L1 CELLS; ADIPONECTIN; ADIPOSE TISSUE; ADULT; ANIMALS; ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; MALE; MICE; PROCETOFEN; RATS; RATS, SPRAGUE-DAWLEY; RETINOL-BINDING PROTEINS, PLASMA;

EID: 65649120733     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90526.2008     Document Type: Article

References (34)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.
2. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein (RBP4) in obese children by lifestyle intervention: association with sub-clinical inflammation. J Clin Endocrinol Metab 92: 1971-1974, 2007. (Pubitemid 46997219)
3. Blaner WS. Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev 10: 308-316, 1989.
4. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29: 2457-2461, 2006.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001.
6. Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 42: 39-64, 2006.
7. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson P, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354: 2552-2563, 2006. (Pubitemid 43882351)
8. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91: 11012-11016, 1994. (Pubitemid 24349615)
9. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M, Ludvik B. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 92: 1168-1171, 2007. (Pubitemid 46465698)
10. Hammarstedt A, Pihlajamäki J, Graham TE, Kainulainen S, Kahn BB, Laakso M, Smith U. High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naive type 2 diabetic subjects. J Intern Med 263: 440-449, 2008.
11. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D, Matas Z, Hibuse T, Fujita K, Nishizawa H, Adler Y, Motro M, Kihara S, Shimomura I, Behar S, Funahashi T. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin Level. Arterioscler Thromb Vasc Biol 27: 635-641, 2007. (Pubitemid 46263411)
12. Hutchison SK, Harrison C, Stepto N, Meyer C, Teede HJ. Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome. Diabetes Care 7: 1427-1432, 2008.
13. Iannucci CV, Capoccia D, Calabria M, Leonetti F. Metabolic syndrome and adipose tissue: new clinical aspects and therapeutic targets. Curr Pharm Des 13: 2148-2168, 2007. (Pubitemid 47078770)
14. Jia W, Wu H, Bao Y, Wang C, Zhu J, Xiang K. Association of serum retinol binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrinol Metab 92: 3224-3229, 2007. (Pubitemid 47236396)
15. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402-2410, 2000. (Pubitemid 32269192)
16. Kissebah AH, Peiris AN, Evans DJ. Mechanisms associating body fat distribution to glucose intolerance and diabetes mellitus: window with a view. Acta Med Scand Suppl 723: 79-89, 1988.
17. Klöting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, Fasshauer M, Schön MR, Stumvoll M, Blüher M, Kahn BB. Serum retinol binding protein 4 (RBP4) is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker for intraabdominal adipose tissue mass. Cell Metab 6: 79-87, 2007. (Pubitemid 46995778)
18. Lamb RG, Koch JC, Bush SR. An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion. Biochim Biophys Acta 1165: 299-305, 1993.
19. Larsen PJ, Jensen PB, Sorensen RV, Larsen LK, Vrang N, Wulff EM, Wassermann K. Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes 52: 2249-2259, 2003. (Pubitemid 37059494)
20. Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism 56: 327-331, 2007.
21. Lee JW, Im JA, Lee HR, Shim JY, Youn BS, Lee DC. Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women. Obesity (Silver Spring) 15: 2225-2232, 2007.
22. Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V, Goglia F. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett 491: 154-158, 2001. (Pubitemid 32172021)
23. Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W, Kleemann R, Bakker A, Veenman F, Wahli W, Mü ller M, Kersten S. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 279: 34411-34420, 2004. (Pubitemid 39318067)
24. Morin CL, Eckel RH, Marcel T, Pagliassotti MJ. High fat diets elevate adipose tissue-derived tumor necrosis factor α activity. Endocrinology 138: 4665-4671, 1997. (Pubitemid 27460901)
25. Murali B, Upadhyaya UM, Goyal RK. Effect of chronic treatment with Enicostemma littorale in non-insulin-dependent diabetic rats. J Ethnopharmacol 81: 199-204, 2002. (Pubitemid 34628502)
26. Naderali EK, Fatani S, Telles M, Hunter L. The effects of physiological and pharmacological weight loss on adiponectin and leptin mRNA levels in the rat epididymal adipose tissue. Eur J Pharmacol 579: 433-438, 2008.
27. Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Canu T, Ragogna F, Scifo P, Del Maschio A, Luzi L. Serum retinol binding protein-4, leptin and adiponectin concentrations are related to ectopic fat accumulation. J Clin Endocrinol Metab 92: 4883-4888, 2007. (Pubitemid 350223473)
28. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789, 1963.
29. Seo JA, Kim NH, Park SY, Kim HY, Ryu OH, Lee KW, Lee J, Kim DL, Choi KM, Baik SH, Choi DS, Kim SG. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) 68: 555-560, 2008.
30. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, Fritsche A, Häring HU. High circulating retinol-binding protein 4 is associated with elevated liver fat, but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 30: 1173-1178, 2007. (Pubitemid 46684644)
31. Student AK, Hsu RY, Lane MD. Induction of fatty acid synthetase synthesis in differentiating 3T3-L1 preadipocytes. J Biol Chem 255: 4745-4750, 1980.
32. Wu H, Jia W, Bao Y, Lu J, Zhu J, Wang R, Chen Y, Xiang K. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 79: 185-190, 2008.
33. Yagmur E, Weiskirchen R, Gressner AM, Trautwein C, Tacke F. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. Diabetes Care 30: 1168-1172, 2007. (Pubitemid 46684643)
34. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 356-362, 2005. (Pubitemid 41065039)